Philadelphia-based Passage Bio is aiming to treat frontotemporal dementia by using an AAV gene therapy to boost progranulin levels in the brain

blonca9
Jul 10, 2024
1 min read

CEO William Chou describes the scientific rationale for elevating progranulin, what the company has seen in the first three patients treated, and previews an upcoming conference in September.

Recent Posts

See All

ASCO 2025: France based Transgene presented data for its personalized cancer vaccine in the adjuvant setting for HPV- head and neck cancer

ASCO 2025: Candel Therapeutics CEO Paul Peter Tak describes phase 3 prostate cancer data from the company's off-the-shelf, adeno delivered, cancer immunotherapy

ASCO 2025: Strand Therapeutics Co-Founder & CEO Jake Becraft discusses the clinical data presentation for the company's IL-12, self-replicating mRNA cancer immunotherapy

Philadelphia-based Passage Bio is aiming to treat frontotemporal dementia by using an AAV gene therapy to boost progranulin levels in the brain

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight